Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Affymax said that patients taking part in its phase I trial of anemia drug Hematide demonstrated a statistically significant increase in red blood cells, which was sustained for at least one month.
Subscribe to our email newsletter
Single doses of Hematide resulted in dose-dependent increases in circulating reticulocytes in normal healthy volunteers and in a clinically and statistically significant increase in red blood cells and hemoglobin from baseline, the company said.
Hematide, the company's first product candidate to enter the clinic, is a novel peptide-based drug designed to stimulate the production of red blood cells. It is currently in phase II trials for the treatment of anemia associated with chronic kidney disease and in anemic cancer patients undergoing chemotherapy.